Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Noval transcript, antisense to USP39" (ENSG00000305171) is annotated as a noncoding RNA gene that runs antisense to the coding gene USP39[1]. Antisense transcripts frequently play regulatory roles in gene expression, often impacting the stability, transcription rate, or epigenetic state of their sense gene counterparts[3][4]. However, there is no published characterization of the molecular or therapeutic roles of this specific transcript, no evidence that it is a therapeutic target, and very little structured information about its expression, regulation, or biological properties[1]. The entry is limited, and its designation as a therapeutic target is not supported in current databases or literature. There is incorrect or missing information for this entity with respect to drug targeting. It is not a protein-coding gene, has no established functional annotation or known disease associations, and is not a recognized therapeutic target under current definitions[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to USP39.